Distribution of alleles, genotypes and haplotypes of the CYP2B6 (rs3745274; rs2279343) and CYP3A4 (rs2740574) genes in the Malian population: Implication for pharmacogenetics.
Journal
Medicine
ISSN: 1536-5964
Titre abrégé: Medicine (Baltimore)
Pays: United States
ID NLM: 2985248R
Informations de publication
Date de publication:
23 Jul 2021
23 Jul 2021
Historique:
received:
31
03
2020
accepted:
22
06
2021
entrez:
16
8
2021
pubmed:
17
8
2021
medline:
24
8
2021
Statut:
ppublish
Résumé
Cytochrome P450 enzymes play a central role in the phase I biotransformation process of a wide range of compounds, including xenobiotics, drugs, hormones and vitamins. It is noteworthy that these enzymes are highly polymorphic and, depending on the genetic makeup, an individual may have impaired enzymatic activity. Therefore, the identification of genetic variants in these genes could facilitate the implementation of pharmacogenetic studies and genetic predisposition to multifactorial diseases. We have established the frequencies of CYP2B6 (rs3745274; rs2279343) and CYP3A4 (rs2740574) alleles and genotypes in 209 healthy Malian subjects using TaqMan drug metabolism genotyping assays for allelic discrimination. Allele frequencies were 37% for CYP2B6 rs3745274; 38% for CYP2B6 rs2279343; and 75% for CYP3A4 rs2740574 respectively. Overall, the frequencies observed in Mali are statistically comparable to those reported across Africa except North Africa. The major haplotypes in CYP2B6 rs3745274 and CYP2B6 rs2279343 were represented by GA (60.24%) followed by TG (35.36%). We noted a strong linkage disequilibrium between CYP2B6 rs3745274 and CYP2B6 rs2279343 with D' = 0.91 and r2 = 0.9. The frequencies of the genotypic combinations were 43.5% (GT/AG), 37.3% (GG/AA) and 11.5% (TT/GG) in the combination of CYP2B6-rs3745274 and CYP2B6-rs2279343; 26.8% (GT/CC), 25.4%, (GT/CT), 17.2% and GG/CT in the combination CYP2B6-rs3745274-CYP3A4-rs2740574; 26.8% (AG/CC), 23.9% (AA/CC), 19.1% (AG/CT), and 11% (AA/CT) in the combination CYP2B6-rs2279343-CYP3A4-rs2740574, respectively. The most common triple genotype was GT/AG/CC with 24.9%, followed by GG/AA/CC with 23.9%, GT/AG/CT with 16.7%, and GG/AA/CT with 10%. Our results provide new insights into the distribution of these pharmacogenetically relevant genes in the Malian population. Moreover, these data will be useful for studies of individual genetic variability to drugs and genetic predisposition to diseases.
Identifiants
pubmed: 34398016
doi: 10.1097/MD.0000000000026614
pii: 00005792-202107230-00018
pmc: PMC8294905
doi:
Substances chimiques
Cytochrome P-450 CYP2B6
EC 1.14.14.1
Cytochrome P-450 CYP3A
EC 1.14.14.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e26614Subventions
Organisme : European and Developing Countries Clinical Trials Partnership
ID : EDCTP2-TMA2016 TMA2016CDF
Informations de copyright
Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.
Déclaration de conflit d'intérêts
The authors have no conflicts of interest to disclose.
Références
Manikandan P, Nagini S. Cytochrome P450 structure, function and clinical significance: a review. Curr Drug Targets 2017;19:38–54.
Pikuleva IA. Cytochrome P450 s and cholesterol homeostasis. Pharmacol Ther 2006;112:761–73.
Durairaj P, Fan L, Du W, Ahmad S, Mebrahtu D, Sharma S, et al. Functional expression and activity screening of all human cytochrome P450 enzymes in fission yeast. FEBS Lett 2019;593:1372–80.
Xie F, Ding X, Zhang QY. An update on the role of intestinal cytochrome P450 enzymes in drug disposition. Acta Pharm Sin B 2016;6:374–83.
Purnapatre K, Khattar SK, Saini KS. Cytochrome P450 s in the development of target-based anticancer drugs. Cancer Lett 2008;259:01–15.
Oostendorp RL, Marchetti S, Beijnen JH, Mazzanti R, Schellens JHM. The effect of hydroxyurea on P-glycoprotein/BCRP-mediated transport and CYP3A metabolism of imatinib mesylate. Cancer Chemother Pharmacol 2007;59:855–60.
Peng B, Lloyd P, Schran H. Clinical pharmacokinetics of imatinib. Clin Pharmacokinet 2005;44:879–94.
Van Erp NP, Gelderblom H, Karlsson MO, Li J, Zhao M, Ouwerkerk J, et al. Influence of CYP3A4 inhibition on the steady-state pharmacokinetics of imatinib. Clin Cancer Res 2007;13:7394–400.
Nelson DR. Gene nomenclature by default, or BLASTing to Babel. Hum Genomics 2005;2:196–201.
Lee YH. Assessing the causal association between smoking behavior and risk of gout using a Mendelian randomization study. Clin Rheumatol 2018;37:3099–105.
Ali GT, Al-azhary NM, Mokhtar DA. Frequency and prognostic significant of CYP3A4-A-290G polymorphism in acute myeloid leukemia. J Adv Res 2014;5:657–61.
Ding Y, Li Q, Feng Q, Xu D, Wu C, Zhao J, et al. CYP2B6 genetic polymorphisms influence chronic obstructive pulmonary disease susceptibility in the Hainan population. Int J Chron Obstruct Pulmon Dis 2019;14:2103–15.
Mukonzo JK, Nanzigu S, Waako P, Ogwal-Okeng J, Gustafson LL, Aklillu E. CYP2B6 genotype, but not rifampicin-based anti-TB cotreatments, explains variability in long-term efavirenz plasma exposure. Pharmacogenomics 2014;15:1423–35.
Ferreira PE, Veiga MI, Cavaco I, Martins JP, Andersson B, Mushin S, et al. Polymorphism of antimalaria drug metabolizing, nuclear receptor, and drug transport genes among malaria patients in Zanzibar, east Africa. Ther Drug Monit 2008;30:10–5.
Kassogue Y, Quachouh M, Dehbi H, Quessar A, Benchekroun S, Nadifi S. Functional polymorphism of CYP2B6 G15631T is associated with hematologic and cytogenetic response in chronic myeloid leukemia patients treated with imatinib. Med Oncol 2014;31:782–6.
Mikstacki A, Zakerska-Banaszak O, Skrzypczak-Zielinska M, Tamowicz B, Prendecki M, Dorszewska J, et al. The effect of UGT1A9, CYP2B6 and CYP2C9 genes polymorphism on individual differences in propofol pharmacokinetics among Polish patients undergoing general anaesthesia. J App Genet 2017;58:213–20.
Miao J, Jin Y, Marunde RL, Kim S, Quinney S, Radovich M, et al. Association of genotypes of the CYP3A cluster with midazolam disposition in vivo. Pharmacogenomics J 2009;9:319–26.
Hoffman SMG, Nelson DR, Keeney DS. Organization, structure and evolution of the CYP2 gene cluster on human chromosome 19. Pharmacogenetics 2001;11:687–98.
Tornio A, Backman JT. Cytochrome P450 in pharmacogenetics: an update. 1st ed. Adv Pharmacol 2018.
Nyakutira C, Röshammar D, Chigutsa E, Chonzi P, Ashton M, Nhachi C, et al. High prevalence of the CYP2B6 rs3745274G→T( ∗ 6) variant and effect on the population pharmacokinetics of efavirenz in HIV/AIDS outpatients in Zimbabwe. Eur J Clin Pharmacol 2008;64:357–65.
Penzak SR, Kabuye G, Mugyenyi P, Mbamanya F, Natarajan V, Alfaro RM, et al. Cytochrome P450 2B6 (CYP2B6) Grs3745274T influences nevirapine plasma concentrations in HIV-infected patients in Uganda. HIV Medicine 2007;8:86–91.
Reay R, Dandara C, Viljoen M, Rheeders M. CYP2B6 haplotype predicts efavirenz plasma concentration in black South African HIV-1-infected children: a longitudinal pediatric pharmacogenomic study. OMICS 2017;21:465–73.
Shi WL, Tang HL, Zhai S. Di. Effects of the CYP3A4 ô 1B genetic polymorphism on the pharmacokinetics of tacrolimus in adult renal transplant recipients: a meta-analysis. PLoS One 2015;10:01–14.
McGraw J, Waller D. Cytochrome P450 variations in different ethnic populations. Expert Opin Drug Metab Toxicol 2012;8:371–82.
Solé X, Guinó E, Valls J, Iniesta R, Moreno V. SNPStats: a web tool for the analysis of association studies. Bioinformatics 2006;22:1928–9.
Swart M, Skelton M, Wonkam A, Kannemeyer L, Chin’ombe N, Dandara C. CYP1A2, CYP2A6, CYP2B6, CYP3A4 and CYP3A5 polymorphisms in two Bantu-speaking populations from Cameroon and South Africa: implications for global pharmacogenetics. CPPM 2012;10:43–53.
Rajeev KM, Mark NZ, Peter AZ. Prevalence of CYP2B6 alleles in malaria-endemic populations of West Africa and Papua New Guinea. Eur J Clin Pharmacol 2006;62:267–75.
Toyin A.S. ad, Olugbenga SJ, Ayodele BR, Joseph OO, Moji BOT. Allele and genotype frequencies of cytochrome P450 2B6 rs3745274G > T single nucleotide polymorphism in HIV-negative and HIV-infected adult Nigerian populations. Am J Ther 2016;23:e1715–9.
Hodel EMS, Csajka C, Ariey F, Guidi M, Kabanywanyi AM, Duong S, et al. Effect of single nucleotide polymorphisms in cytochrome P450 isoenzyme and N-acetyltransferase 2 genes on the metabolism of artemisinin-based combination therapies in malaria patients from Cambodia and Tanzania. Antimicrob Agents Chemother 2013;57:950–8.
Rodríguez-Antona C, Sayi JG, Gustafsson LL, Bertilsson L, Ingelman-Sundberg M. Phenotype-genotype variability in the human CYP3A locus as assessed by the probe drug quinine and analyses of variant CYP3A4 alleles. Biochem Biophys Res Commun 2005;338:299–305.
Ellison C, Abou El-Ella S, Tawfik M, Lein P, Olson J. Allele and genotype frequencies of CYP2B6 and CYP2C19 polymorphisms in Egyptian agricultural workers. J Toxicol Environ Health A 2012;75:232–41.
The International Genome Consortium. www.1000Genomes.org .
Ariyoshi N, Ohara M, Kaneko M, Afuso S, Kumamoto T, Nakamura H, et al. Q172H replacement overcomes effects on the metabolism of cyclophosphamide and efavirenz caused by CYP2B6 variant with Arg262. Drug Metab Dispos 2011;39:2045–8.
Marwa KJ, Schmidt T, Sjögren M, Minzi OMS, Kamugisha E, Swedberg G. Cytochrome P450 single nucleotide polymorphisms in an indigenous Tanzanian population: a concern about the metabolism of artemisinin-based combinations. Malar J 2014;13:01–7.
Zeigler-Johnson CM, Walker AH, Mancke B, Spangler E, Jalloh M, McBride S, et al. Ethnic differences in the frequency of prostate cancer susceptibility alleles at SRD5A2 and CYP3A4. Human Hered 2002;54:13–21.
Novillo A, Romero-Lorca A, Gaibar M, Bahri R, Harich N, Sánchez-Cuenca D, et al. Genetic diversity of CYP3A4 and CYP3A5 polymorphisms in North African populations from Morocco and Tunisia. Int J Biol Markers 2015;30:e148–51.
Fernández-Santander A, Novillo A, Gaibar M, et al. Cytochrome and sulfotransferase gene variation in north African populations. Pharmacogenomics 2016;17:1415–23.
Amirimani B, Ning B, Deitz AC, Weber BL, Kadlubar FF, Rebbeck TR. Increased transcriptional activity of the CYP3A4 ∗ 1B promoter variant. Environ Mol Mutagenesis 2003;42:299–305.
Mutagonda RF, Kamuhabwa AAR, Minzi OMS, Massawe SN, Asghar M, Homann MV, et al. Effect of pharmacogenetics on plasma lumefantrine pharmacokinetics and malaria treatment outcome in pregnant women. Malar J 2017;16:01–10.
Zhou LP, Yao F, Luan H, Wang YL, Dong XH, Zhou WW, et al. CYP3A4rs2740574 polymorphism and cancer risk: a HuGE review and meta-analysis. Tumor Biol 2013;34:649–60.
Wang C, Lu e, Chang KP, Guo Z, Qiao ML. Association of CYP3A4rs2740574 genotype with Cyclosporin A pharmacokinetics in renal transplant recipients: a meta-analysis. Gene 2018;664:44–9.
Klein K, Lang T, Saussele T, Barbosa-Sicard E, Schunck WH, Eichelbaum M, et al. Genetic variability of CYP2B6 in populations of African and Asian origin: allele frequencies, novel functional variants, and possible implications for anti-HIV therapy with efavirenz. Pharmacogenet Genomics 2005;15:861–73.
Ellison C, Abou El-Ella S, Tawfik M, Lein P, Olson J. CYP2C19 polymorphisms in Egyptian agricultural workers. J Toxicol Environ Health A 2012;75:232–41.
Ngaimisi E, Habtewold A, Minzi O, Makonnen E, Mugusi S, Amogne W, et al. Importance of ethnicity, CYP2B6 and ABCB1 genotype for efavirenz pharmacokinetics and treatment outcomes: a parallel-group prospective cohort study in two sub-Saharan Africa populations. PLoS One 2013;08.